register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT04160052 | [
{
"id_field": "org_study_id",
"id_value": [
"2019-0368"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-06873"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | This phase I/II trial studies the side effects and best dose of venetoclax when given together with azacitidine in treating patients with high-risk myelodysplastic syndrome that has come back (recurrent) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax and azacitidine, work ... | Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals" | [
{
"description": "Given SC or IV",
"name": "Azacitidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"5 AZC",
"5-AC",
"5-AZC",
"5-Azacytidine",
"Azacytidine",
"Azacytidine, 5-",
"Ladakamycin",
"Mylosar",
"Onureg",
... | [
{
"design_group_description": "Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (venetoclax, azacitidine)",
"... | [
"Chronic Myelomonocytic Leukemia",
"Myelodysplastic Syndrome",
"Recurrent Myelodysplastic Syndrome",
"Refractory Myelodysplastic Syndrome",
"Therapy-Related Myelodysplastic Syndrome"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "阿扎胞苷",
"lang": "CN"
},
{
"name": "Azacitidine",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"code": "59025e2e8d8ee2822d4d2335a24ad9e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PS1638"
}
] |
NCT04808037 | [
{
"id_field": "org_study_id",
"id_value": [
"EAE-2020/MM0107"
]
},
{
"id_field": "acronym",
"id_value": [
"BelaRd"
]
}
] | https://clinicaltrials.gov/study/NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone. | A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | [
{
"description": "Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible",
"name": "Belantamab mafodotin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Blenrep"
],
"type"... | [
{
"design_group_description": "12 patients are anticipated to receive Belantamab Mafodotin 2.5 Q8W = 2.5 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone",
"design_group_title": "Cohort 1, First Part",
"design_group_type": "Experimental",
"design_group_t... | [
"Multiple Myeloma"
] | [
"Hellenic Society of Cardiology"
] | [
"GSK Plc"
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "玛贝兰妥单抗",
"lang": "CN"
},
{
"name": "Belantamab mafodotin",
"lang": "EN"
},
{... | [
{
"identifier_source": [
{
"code": "080aed888ae559220ee52aee022ee885",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "225525228922254222e50525a8e5d352",
"s... |
NCT04827953 | [
{
"id_field": "org_study_id",
"id_value": [
"NLM-2020-01 / NUMANTIA"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-004932-52"
]
},
{
"id_field": "acronym",
"id_value": [
"NUMANTIA"
]
}
] | https://clinicaltrials.gov/study/NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunothera... | Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer | [
{
"description": "Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).",
"name": "Gemcitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).",
... | [
{
"design_group_description": "Conventional Chemotherapy (Gemcitabine + nab-paclitaxel) plus NLM-001 plus Zalifrelimab",
"design_group_title": "Investigational treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"Pancreatic Ductal Adenocarcinoma"
] | [
"Nelum Corp."
] | [
"Agenus, Inc.",
"Apices Soluciones SL"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "3829852583ae092924adeee209a885a5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NUMANTIA"
}
] |
NCT06206837 | [
{
"id_field": "org_study_id",
"id_value": [
"C4891026"
]
},
{
"id_domain": "Alias Study Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"TACTIVE-K"
]
},
{
"id_domain": "CTIS (EU)",
"id_field": "secondary_id",
"id_type"... | https://clinicaltrials.gov/study/NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and ... | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST C... | [
{
"description": "Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days",
"name": "vepdegestrant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ARV-471 / PF... | [
{
"design_group_description": "vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles",
"design_group_title": "vepdegestrant in combination with PF-07220060",
"design_group_type": "Experimental",
"design_grou... | [
"Breast Cancer"
] | [
"Pfizer Inc."
] | [
"Arvinas Estrogen Receptor, Inc."
] | [
[
{
"name": "Atirmociclib",
"lang": "EN"
}
],
[
{
"name": "维普地司他",
"lang": "CN"
},
{
"name": "Vepdegestrant",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0354ede28344328eaed035edd03580d3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "ae2e24a25d5e002542a3e0528a929ed5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TAC... |
NCT02649985 | [
{
"id_field": "org_study_id",
"id_value": [
"2015P002329"
]
},
{
"id_field": "acronym",
"id_value": [
"MAPET"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2015P002329"
]
}
] | https://clinicaltrials.gov/study/NCT02649985 | PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases | The specific aims of the study are:<br/>Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multi... | Microglial Activation PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases | [
{
"description": "PET radiopharmaceutical",
"name": "[F-18]PBR06",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"[F-18] PBR06"
],
"type": "Drug"
},
{
"description": "PET radiopharmaceutical",
"name": "[C-11]PBR28",
"normalized_type": "3d1aa8826... | [
{
"design_group_description": "Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, at least one gadolinium enhancing lesion on a MRI within 12 months of enrollment, or at least one new FLAIR bright lesion on M... | [
"Multiple Sclerosis",
"Alzheimer's Disease"
] | [
"The Brigham & Women's Hospital, Inc."
] | [
"The Massachusetts General Hospital"
] | [
[
{
"name": "[11C]PBR-28",
"lang": "EN"
}
],
[
{
"name": "[18F]-PBR-06",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MAPET"
},
{
"identifier_source": [
{
"code": "8e53ee324eaa288535824a22550de4d8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
... |
NCT00964678 | [
{
"id_field": "org_study_id",
"id_value": [
"HM12120"
]
}
] | https://clinicaltrials.gov/study/NCT00964678 | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension | The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart. | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension | [
{
"description": "twice daily oral treatment in escalating dose",
"name": "Carvedilol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Coreg"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI",
"design_group_title": "carvedilol",
"design_group_type": ... | [
"Pulmonary Arterial Hypertension"
] | [
"Virginia Commonwealth University"
] | [
"GSK Plc"
] | [
[
{
"name": "卡维地洛",
"lang": "CN"
},
{
"name": "Carvedilol",
"lang": "EN"
},
{
"name": "カルベジロール",
"lang": "JP"
}
]
] | null |
NCT01689870 | [
{
"id_field": "org_study_id",
"id_value": [
"LUD2012-005"
]
}
] | https://clinicaltrials.gov/study/NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | This is an open label, two-phase study combining a dose escalation Phase 1 with a proof-of-concept Phase 2 in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated.<br/>The purpose of the Phase 1 is to determine the Anti-OX40 Maximum Tolerated Dose (MTD) and the secondary ob... | Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma | [
{
"description": "Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5",
"name": "Anti-OX40",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CD134 mab"
],
"type": "Drug"
},
{
"description": "Ipilimumab will be ad... | [
{
"design_group_description": "Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.",
"design_group_title": "Phase 1 Cohort 1",
"desi... | [
"Metastatic Melanoma"
] | [
"Ludwig Institute for Cancer Research Ltd."
] | [
"AgonOx LLC"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03299413 | [
{
"id_field": "org_study_id",
"id_value": [
"IBDUJCTC"
]
}
] | https://clinicaltrials.gov/study/NCT03299413 | Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease | Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part via inhibition of neutrophil Myeloperoxidase (MPOx) activity. Inhibiting MPOx should modify disease progression as well ... | Ulcerative Colitis Stem Cell Therapy | [
{
"description": "Wharton Jelly Mesenchymal stem cells will be injected intravenously",
"name": "Wharton Jelly Mesenchymal stem cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each do... | [
"Inflammatory Bowel Diseases"
] | [
"The University of Jordan"
] | [
"Scientific Research Projects"
] | [
[
{
"name": "Wharton jelly mesenchymal stem cells (University of Jordan)",
"lang": "EN"
}
]
] | null |
NCT00006604 | [
{
"id_field": "org_study_id",
"id_value": [
"P1020A"
]
},
{
"id_domain": "DAIDS ES",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"10037"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IMPAACT P1020A"
]
},
{
... | https://clinicaltrials.gov/study/NCT00006604 | Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents | The purpose of this study was to find a safe and tolerable dose of the protease inhibitor (PI) atazanavir (ATV), with or without a low-dose boost of the PI ritonavir (RTV), when taken with other anti-HIV drugs in HIV infected infants, children, and adolescents.<br/>Advancements in anti-HIV drugs for HIV infected childr... | Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents | [
{
"description": "Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.",
"name": "ATV",
"normalized_type": "3d1aa88261d64c03841372397... | [
{
"design_group_description": "Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.<br/>ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established",
"design_group_title": "Step I: Group 1",
"design_group_type": "Experimental",
"... | [
"HIV Infections"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "硫酸阿扎那韦",
"lang": "CN"
},
{
"name": "Atazanavir Sulfate",
"lang": "EN"
},
{
"name": "アタザナビル硫酸塩",
"lang": "JP"
}
],
[
{
"name": "利托那韦",
"lang": "CN"
},
{
"name": "Ritonavir",
"lang": "EN"
},
{
... | null |
NCT02004275 | [
{
"id_field": "org_study_id",
"id_value": [
"A061202"
]
},
{
"id_domain": "Clinical Trial Reporting Program",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2013-01702"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. N... | https://clinicaltrials.gov/study/NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomal... | A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy | [
{
"description": "given PO",
"name": "pomalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pomalyst®"
],
"type": "Drug"
},
{
"description": "given PO",
"name": "ixazomib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"othe... | [
{
"design_group_description": "Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.",
"design_group_titl... | [
"Multiple Myeloma in Relapse"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute",
"Millennium Pharmaceuticals, Inc.",
"Celgene Corp."
] | [
[
{
"name": "枸橼酸伊沙佐米",
"lang": "CN"
},
{
"name": "Ixazomib citrate",
"lang": "EN"
},
{
"name": "イキサゾミブクエン酸エステル",
"lang": "JP"
}
],
[
{
"name": "泊马度胺",
"lang": "CN"
},
{
"name": "Pomalidomide",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"code": "023e22e854e0a44d0ee5228205e50554",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "200823e2a5e5a88229ea5282d803434e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT04446897 | [
{
"id_field": "org_study_id",
"id_value": [
"IBCE_MSC(periodontitis)"
]
}
] | https://clinicaltrials.gov/study/NCT04446897 | Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction | Treatment of chronic medium-severe periodontitis with mesenchymal stem cells and mesenchymal stem cells predifferentiated in osteogenic direction | Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction Immobilised on a Biodegradable Carrier | [
{
"description": "autologous mesenchymal stem cells",
"name": "mesenchymal stem cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "standard treatment according to clinical protocols",
"name": "standard treatment",
"normalized_type... | [
{
"design_group_description": "standard treatment according to clinical protocols plus mesenchymal stem cells",
"design_group_title": "mesenchymal stem cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Periodontitis, Chronic"
] | [
"The National Academy of Sciences of Belarus"
] | [
"Belarusian Medical Academy of Post Graduate Education"
] | [
[
{
"name": "Mesenchymal Stem Cells(Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus)",
"lang": "EN"
}
]
] | null |
NCT04589832 | [
{
"id_field": "org_study_id",
"id_value": [
"MEL18-372"
]
}
] | https://clinicaltrials.gov/study/NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO) will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after every 2 cycles. Treatment will continue until d... | Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | [
{
"description": "Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive... | [
{
"design_group_description": "Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIS... | [
"Uveal Melanoma"
] | [
"Hoosier Cancer Research Network"
] | [
"Genentech, Inc.",
"Vanquish Oncology, Inc."
] | [
[
{
"name": "PAC-1",
"lang": "EN"
}
],
[
{
"name": "恩曲替尼",
"lang": "CN"
},
{
"name": "Entrectinib",
"lang": "EN"
},
{
"name": "エヌトレクチニブ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2e9920e2d0e4952d454322e4a0e800dd",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "###DELETE"
},
{
"identifier_source": [
{
"code": "28eeaa25524ee80e20e2e252d242a02d",
"source": "CT_RESULT... |
NCT06885281 | [
{
"id_field": "org_study_id",
"id_value": [
"ZL-1310-002"
]
}
] | https://clinicaltrials.gov/study/NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors | A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors | [
{
"description": "drug ZL-1310",
"name": "ZL-1310",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "ZL-1310 as a single agent",
"design_group_title": "Single Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "drug ZL-1310",
"interv... | [
"Solid Tumors"
] | [
"Zai Lab (Shanghai) Co., Ltd."
] | [
"Zai Lab Ltd. (United States)"
] | [
[
{
"name": "Zocilurtatug Pelitecan",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "50e85e39e58222248405ee3d88824923",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ZL-1310-002"
}
] |
NCT05180422 | [
{
"id_field": "org_study_id",
"id_value": [
"02AT21-KRAS"
]
}
] | https://clinicaltrials.gov/study/NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | This is a multicenter, non-randomized, open-label, phase I/II study to evaluate the safety and tolerability of AMG 510 plus MVASI in subjects with advanced KRAS p.G12C mutant non-small cell lung cancer (NSCLC) with small, untreated brain metastases. | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis. | [
{
"description": "Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.",
"name": "AMG 510",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).",... | [
{
"design_group_description": "AMG 510/MVASI",
"design_group_title": "Dose Expansion",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Continuous once daily (QD) oral dosing... | [
"Non Small Cell Lung Cancer"
] | [
"CRITERIUM, Inc."
] | [
"Amgen, Inc."
] | [
[
{
"name": "贝伐珠单抗生物类似药（安进）",
"lang": "CN"
},
{
"name": "Bevacizumab-awwb",
"lang": "EN"
},
{
"name": "ベバシズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "索托拉西布",
"lang": "CN"
},
{
"name": "Sotorasib",
"lang": "EN"
}... | null |
NCT05827835 | [
{
"id_field": "org_study_id",
"id_value": [
"TXB2022023"
]
}
] | https://clinicaltrials.gov/study/NCT05827835 | CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases | This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases | A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic Diseases | [
{
"description": "CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases",
"name": "CD7 CAR-T cells injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "In this study, Allogeneic hematopoietic s... | [
{
"design_group_description": "R/R CD7+Malignant Hematologic Diseases",
"design_group_title": "Treatment Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "CD7 CAR T ce... | [
"Hematologic Diseases",
"Neoplasms"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "Anti-CD7 CAR-T cell therapy (Yake Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT06501768 | [
{
"id_field": "org_study_id",
"id_value": [
"CARDIOGEN"
]
},
{
"id_field": "acronym",
"id_value": [
"CARDIOGEN"
]
}
] | https://clinicaltrials.gov/study/NCT06501768 | Cardiovascular Genistein Therapy for Heart Failure Inflammation | This Phase 1b/2a open-label study is designed to assess the safety and efficacy of genistein in patients with heart failure (HF). The investigation will focus on its impact on inflammatory and cardiometabolic biomarkers, as well as its effects on cardiac function and exercise capacity.<br/>Blood samples will be collect... | A Pilot Clinical Trial of Cardiovascular Genistein Therapy for Heart Failure Inflammation | [
{
"description": "Escalation genistein dosing, followed by wash-out period",
"name": "Genistein",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood samples are collected. And then, patients will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before blood are collected. Afterward, patients will take 7... | [
"Heart Failure"
] | [
"UMC Ljubljana"
] | [
"Greenstone Biosciences, Inc."
] | [
[
{
"name": "染料木素",
"lang": "CN"
},
{
"name": "Genistein",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CARDIOGEN"
}
] |
NCT06706050 | [
{
"id_field": "org_study_id",
"id_value": [
"S23004-01"
]
}
] | https://clinicaltrials.gov/study/NCT06706050 | Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index | The purpose of this clinical trial is to assess the skin hydration and transepidermal water loss improvement, pruritus relief, and microbiome alteration effects of a Lactobacillus sp. product (Lactobarriome 5% cream) compared to a placebo cream to prove the skin improvement effects of Lactobarriome 5%, which is a natur... | Clinical Evaluation of Lactobarriome 5% Cream's Efficacy on Dry Skin for Improving Skin Hydration and Transepidermal Water Loss, Relieving Pruritus, and Altering the Skin Microbiome | [
{
"description": "Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis",
"name": "Microbiome Therapeutic LP-51",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "placebo cream (M23004-03) was applied on the partic... | [
{
"design_group_description": "test substance was applied on participants",
"design_group_title": "Arm 1: LP-51",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Microbiome ... | [
"Xerosis"
] | [
"Soon Chun Hyang University"
] | [
"National Research Foundation of Korea",
"Soon Chun Hyang University"
] | [
[
{
"name": "Lactobarriome 5% Cream",
"lang": "EN"
}
]
] | null |
NCT02843815 | [
{
"id_field": "org_study_id",
"id_value": [
"NK-nsclc"
]
}
] | https://clinicaltrials.gov/study/NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced NSCLC. | null | [
{
"description": "Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)",
"name": "Cryosurgery",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"description": "Natural killer cell (each treatment: about 10 billion cells transfu... | [
{
"design_group_description": "In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests ... | [
"Non-small Cell Lung Cancer Metastatic"
] | [
"Fudan University Cancer Hospital"
] | [
"Shenzhen Hanke Bioengineering Co., Ltd."
] | [
[
{
"name": "NK cell therapy (Shenzhen Hank Bioengineering Institute)",
"lang": "EN"
}
]
] | null |
NCT04746183 | [
{
"id_field": "org_study_id",
"id_value": [
"UoL001542i, UoL001542j"
]
},
{
"id_field": "acronym",
"id_value": [
"AGILE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UoL001542i, UoL001542j"
]
},
{
"id_field": "bridge_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT04746183 | AGILE (Early Phase Platform Trial for COVID-19) | The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one mas... | AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment | [
{
"description": "CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.<br/>Phase II: As per Pha... | [
{
"design_group_description": "EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may ... | [
"Covid19"
] | [
"The University of Liverpool"
] | [
"University of Cambridge",
"Royal Liverpool Hospital",
"Liverpool School of Tropical Medicine"
] | [
[
{
"name": "奈玛特韦/利托那韦",
"lang": "CN"
},
{
"name": "Nirmatrelvir/Ritonavir",
"lang": "EN"
},
{
"name": "ニルマトレルビル/リトナビル",
"lang": "JP"
}
],
[
{
"name": "瑞德西韦",
"lang": "CN"
},
{
"name": "Remdesivir",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "82da355e23ea28aea823eaae94a5840d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "AGILE"
}
] |
NCT04313400 | [
{
"id_field": "org_study_id",
"id_value": [
"AMTX100-AD-01"
]
}
] | https://clinicaltrials.gov/study/NCT04313400 | Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis | This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates safety and efficacy of 1.1% w/w AMTX-100 CF versus placebo (vehicle).<br/>The study has two parts:<br/>Phase I (Part 1):<br/>Approximately Twenty-five (25) subjects with various treatable Body Surface Area (BSA) invol... | A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis | [
{
"description": "AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient",
"name": "1.1% w/w AMTX-100 CF-part1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Topical cream manufactured to mimic AMTX-100 CF3",
"name": "Place... | [
{
"design_group_description": "Open-label, five (5) cohorts were sequentially enrolled. AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)",
"design_group_title": "P... | [
"Atopic Dermatitis"
] | [
"Amytrx Therapeutics, Inc."
] | [
"Amarex Clinical Research LLC"
] | [
[
{
"name": "AMTX-100",
"lang": "EN"
}
]
] | null |
NCT04725331 | [
{
"id_field": "org_study_id",
"id_value": [
"BT-001.01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-000505-80"
]
},
{
"id_domain": "Merck Sharp & Dohme LLC",
"id_field": "secondary_id",
"id_type": "Other Identifier",... | https://clinicaltrials.gov/study/NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab. | A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors. | [
{
"description": "Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A]; one dose lower and at Recommended Dose for Part B [Phase I, Part B] by intra-tumoral (IT) route.",
"name": "BT-001",
"n... | [
{
"design_group_description": "Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.",
"design_group_title": "Phase I, Part A - Dose escalation and safety of BT-001 alone",
"design_group_type": "Experimental",... | [
"Metastatic Cancer",
"Soft Tissue Sarcoma",
"Merkel Cell Carcinoma",
"Melanoma",
"Triple Negative Breast Cancer",
"Non Small Cell Lung Cancer"
] | [
"Transgene SA"
] | [
"Merck Sharp & Dohme Corp.",
"BioInvent International AB"
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "BT-001(Transgene)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0a9aa025522eaa2552e0ee408a5d95ed",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BT-001.01"
}
] |
NCT01037088 | [
{
"id_field": "org_study_id",
"id_value": [
"200614658"
]
},
{
"id_domain": "Center for Medicinal Cannabis Research",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"C06-DA-119"
]
}
] | https://clinicaltrials.gov/study/NCT01037088 | Effects of Vaporized Marijuana on Neuropathic Pain | This study theorized that a low dose of vaporized cannabis could alleviate nerve injury pain. | CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain | [
{
"description": "3.53% THC by weight",
"name": "Mild dose cannabis",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"marijuana"
],
"type": "Drug"
},
{
"description": "1.29% THC by weight",
"name": "Low dose cannabis",
"normalized_type": "3d1aa88... | [
{
"design_group_description": "3.53% THC by weight",
"design_group_title": "Mild dose cannabis",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "3.53% THC by weight",
... | [
"Neuropathic Pain",
"Reflex Sympathetic Dystrophy",
"Peripheral Neuropathy",
"Post-herpetic Neuralgia",
"Spinal Cord Injury",
"Multiple Sclerosis"
] | [
"University of California, Davis"
] | [
"Center for Medicinal Cannabis Research"
] | [
[
{
"name": "屈大麻酚",
"lang": "CN"
},
{
"name": "Dronabinol",
"lang": "EN"
}
]
] | null |
NCT03052933 | [
{
"id_field": "org_study_id",
"id_value": [
"COPGEM"
]
}
] | https://clinicaltrials.gov/study/NCT03052933 | Copanlisib and Gemcitabine in Relapsed/Refractory PTCL | COPGEM (Copanlisib and Gemcitabine)chemotherapy regimen is proposed as the salvage treatment for relapsed or refractory peripheral T-cell or NK/T-cell lymphomas in this study protocol, which would be expected to be feasible and effective in this group of patients.<br/>Copanlisib (BAY 80-6946), a highly selective and po... | Prospective, Multicenter, Open-labeled, Phase I/II Study of the Efficacy and Safety of Copanlisib (BAY 80-6946) and Gemcitabine Combination in Patients With Relapsed/Refractory Peripheral T-cell or NK/T-cell Lymphoma | [
{
"description": "For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1... | [
{
"design_group_title": "Copanlisib/gemcitabine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "For phase I study, participants will receive copanlisib (in combination with ge... | [
"Mature T-Cell and NK-Cell Neoplasm"
] | [
"Chonnam National University Hospital"
] | [
"Bayer AG"
] | [
[
{
"name": "盐酸可泮利塞",
"lang": "CN"
},
{
"name": "Copanlisib dihydrochloride",
"lang": "EN"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lan... | [
{
"identifier_source": [
{
"code": "a99a288ad058844da29a58a2a5a52d24",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "COSMOS"
}
] |
NCT00369447 | [
{
"id_field": "org_study_id",
"id_value": [
"YMB1000-010"
]
}
] | https://clinicaltrials.gov/study/NCT00369447 | A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer | This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer. The purpose of the Phase I portion of the study is to evaluate the safety and feasibility of the administration of nimotuzumab with palliative radiation in p... | A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC | [
{
"description": "Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable",
"name": "External radiotherapy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"description": "weekly dose until disease progressio... | [
{
"design_group_description": "200 mg dose",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Radiotherapy for first 2 weeks, 10 daily fractions of... | [
"Non-small-cell Lung Cancer"
] | [
"YM BioSciences, Inc."
] | [
"CIMYM Biosciences, Inc."
] | [
[
{
"name": "尼妥珠单抗",
"lang": "CN"
},
{
"name": "Nimotuzumab",
"lang": "EN"
}
]
] | null |
NCT02751255 | [
{
"id_field": "org_study_id",
"id_value": [
"2015-003862-10"
]
},
{
"id_field": "acronym",
"id_value": [
"DARA/ATRA"
]
}
] | https://clinicaltrials.gov/study/NCT02751255 | Daratumumab in Combination With ATRA | Multiple myeloma (MM) patients who develop bortezomib and lenalidomide-resistant disease have a very poor survival of only a median of 9 months, indicating that new agents are urgently needed. Recent studies have shown that daratumumab as a single agent is effective and well tolerated in these heavily pretreated MM pat... | A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma | [
{
"description": "Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is... | [
{
"design_group_description": "In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients ex... | [
"Multiple Myeloma"
] | [
"Stichting Onderzoek Cancer Center Amsterdam"
] | [
"Vejle Hospital",
"Erasmus Universitair Medisch Centrum Rotterdam",
"University Medical Center of Utrecht",
"University of Turin"
] | [
[
{
"name": "维A酸",
"lang": "CN"
},
{
"name": "Tretinoin",
"lang": "EN"
},
{
"name": "トレチノイン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DARA/ATRA"
}
] |
NCT02602483 | [
{
"id_field": "org_study_id",
"id_value": [
"JAN12006-01"
]
}
] | https://clinicaltrials.gov/study/NCT02602483 | Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD). | The objetive of this study is to explore the efficacy and safety of a triple combination of ibuprofen, magnesium and ascorbic acid for acute pain treatment in TMJD patients | Randomized, Double Blind, Placebo Controlled Exploratory Study To Assess the Efficacy and Safety of a Triple Combination of Ibuprofen+Mg+Ascorbic Acid for Acute Pain Treatment in Temporomandibular Join Disorder (TMJD) Patients | [
{
"name": "Ibuprofen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Magnesium",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Ascorbic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Powder for oral administration",
"design_group_title": "Triple combination",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Ibuprofen",
"int... | [
"Temporomandibular Joint Disorders"
] | [
"Spherium Biomed SL"
] | [
"Hospital Universitario La Fe",
"Universitat Internacional de Catalunya"
] | [
[
{
"name": "维生素C",
"lang": "CN"
},
{
"name": "Ascorbic Acid",
"lang": "EN"
},
{
"name": "アスコルビン酸",
"lang": "JP"
}
],
[
{
"name": "布洛芬",
"lang": "CN"
},
{
"name": "Ibuprofen",
"lang": "EN"
},
{
"name": ... | null |
NCT03617328 | [
{
"id_field": "org_study_id",
"id_value": [
"20085"
]
},
{
"id_field": "acronym",
"id_value": [
"Mel-65"
]
}
] | https://clinicaltrials.gov/study/NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide ISA-51 and polyICLC. The investigators will... | Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | [
{
"description": "6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides",
"name": "6MHP",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"6 melanoma helper peptide vaccine"
],
"type": "Biological"
},
{
"description": "Montanide... | [
{
"design_group_description": "200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg... | [
"Melanoma"
] | [
"University of Virginia"
] | [
"Celldex Therapeutics, Inc."
] | [
[
{
"name": "聚肌胞",
"lang": "CN"
},
{
"name": "Poly ICLC",
"lang": "EN"
}
],
[
{
"name": "瓦利鲁单抗",
"lang": "CN"
},
{
"name": "Varlilumab",
"lang": "EN"
}
],
[
{
"name": "6-melanoma helper peptide vaccine(University of Vi... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Mel-65"
}
] |
NCT05616624 | [
{
"id_field": "org_study_id",
"id_value": [
"202301032"
]
}
] | https://clinicaltrials.gov/study/NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase... | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | [
{
"description": "-Given 60 minutes (+/- 15 minutes) prior to docetaxel",
"name": "ADI-PEG 20",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PEGylated arginine deiminase"
],
"type": "Drug"
},
{
"description": "-Given over the course of 90 minutes (+/-... | [
{
"design_group_description": "* ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.<br/>* Gemcitabine is given intrave... | [
"Non Small Cell Lung Cancer",
"Non-small Cell Lung Cancer",
"Small-cell Lung Cancer",
"Small Cell Lung Carcinoma"
] | [
"Washington University School of Medicine"
] | [
"Polaris Group"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
... | null |
NCT02074046 | [
{
"id_field": "org_study_id",
"id_value": [
"CLP-001"
]
},
{
"id_domain": "The research fund of Fuda cancer hospital in Guangzhou",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"201401"
]
}
] | https://clinicaltrials.gov/study/NCT02074046 | Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer | Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically ... | Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas | [
{
"name": "cancer stem cell vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.",
"design_group_title": "non-cancer stem cell vaccine",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"in... | [
"Neoplasms, Pancreas"
] | [
"Fudan University Cancer Hospital"
] | [
"University of Michigan"
] | [
[
{
"name": "Cancer stem cell vaccine(Fuda Cancer Hospital)",
"lang": "EN"
}
]
] | null |
NCT00385047 | [
{
"id_field": "org_study_id",
"id_value": [
"WRAIR 1280"
]
},
{
"id_domain": "WRAIR Protocol ID",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"A-13949"
]
},
{
"id_domain": "E-Track",
"id_field": "secondary_id",
"id_type": "... | https://clinicaltrials.gov/study/NCT00385047 | A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults | The purpose of this study is to determine whether 2 investigational malaria vaccines are safe as well as protective against malaria in adults living in the United States | Phase I/IIa Study of the Safety, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge of FMP2.1/AS01B and FMP2.1/AS02A Candidate Malaria Vaccines Administered Intramuscularly at Months 0, 1, and 2 in Malaria-naive Adults Living in the United States | [
{
"name": "Group A FMP2.1/AS01B",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"FMP 2.1 50 μg FMP2.1/AS01B"
],
"type": "Biological"
},
{
"name": "Group B FMP2.1/AS02A",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"F... | [
{
"design_group_description": "FMP 2.1 50 μg FMP2.1/AS01B",
"design_group_title": "Group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Group A FMP2.1/AS01B",
"interve... | [
"Malaria"
] | [
"U S Army Medical Research & Development Command"
] | [
"Path Malaria Vaccine Initiative",
"GSK Plc"
] | [
[
{
"name": "FMP2.1/AS01B",
"lang": "EN"
}
],
[
{
"name": "FMP 2.1 malaria vaccine(Walter Reed Army Institute of Research)",
"lang": "EN"
}
]
] | null |
NCT00681252 | [
{
"id_field": "org_study_id",
"id_value": [
"IMS-MKA0201"
]
}
] | https://clinicaltrials.gov/study/NCT00681252 | Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer | The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51. | Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer | [
{
"description": "Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.",
"name": "URLC10, VEGFR1 ... | [
{
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1... | [
"Gastric Cancer"
] | [
"University of Tokyo"
] | [
"University of Tokyo"
] | [
[
{
"name": "HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)",
"lang": "EN"
}
]
] | null |
NCT00630396 | [
{
"id_field": "org_study_id",
"id_value": [
"R01NS055728-01A1"
]
},
{
"id_domain": "GHSU Human Assurance Committee number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"07-02-202"
]
},
{
"id_field": "acronym",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00630396 | Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke | The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients. | Minocycline to Improve Neurologic Outcome in Stroke (MINOS) | [
{
"description": "Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.<br/>Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.<br/>Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by... | null | [
"Stroke, Acute"
] | [
"Augusta University"
] | [
"National Institute of Neurological Disorders & Stroke",
"University of Kentucky",
"Oregon Health & Science University"
] | [
[
{
"name": "盐酸米诺环素",
"lang": "CN"
},
{
"name": "Minocycline Hydrochloride",
"lang": "EN"
},
{
"name": "ミノサイクリン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MINOS"
}
] |
NCT06704191 | [
{
"id_field": "org_study_id",
"id_value": [
"MC240502"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UL1TR002377"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type"... | https://clinicaltrials.gov/study/NCT06704191 | In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different wa... | MC240502: Cancer CARE (Connected Access and Remote Expertise) Beyond Walls In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes | [
{
"description": "Given intravesically",
"name": "BCG Solution",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Bacillus Calmette Guerin Solution",
"Bacillus Calmette-Guerin Solution",
"TICE BCG Solution"
],
"type": "Biological"
},
{
"descri... | [
{
"design_group_description": "INDUCTION (PHASE IB COHORT AND PHASE II COHORT): Patients receive BCG intravesically over 1-2 hours, gemcitabine intravesically over 1-2 hours, gemcitabine intravesically over 1 hour followed by docetaxel intravesically over 1 hour or mitomycin C intravesically over 1-2 hours in t... | [
"Non-Muscle Invasive Bladder Carcinoma",
"Stage 0a Bladder Cancer AJCC v8",
"Stage I Bladder Cancer AJCC v8",
"Stage 0is Bladder Cancer AJCC v8"
] | [
"Mayo Clinic"
] | [
"National Center for Advancing Translational Sciences"
] | [
[
{
"name": "丝裂霉素",
"lang": "CN"
},
{
"name": "Mitomycin",
"lang": "EN"
},
{
"name": "マイトマイシンC",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MC240502"
}
] |
NCT05485753 | [
{
"id_field": "org_study_id",
"id_value": [
"GNC-038-103"
]
}
] | https://clinicaltrials.gov/study/NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MT... | An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of Tetra-specific Antibody GNC-038 Injection in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Centr... | [
{
"description": "Administration by intravenous infusion",
"name": "GNC-038",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or othe... | [
"Primary Central Nervous System Lymphoma",
"Secondary Central Nervous System Lymphoma"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd.",
"Systimmune, Inc."
] | [
[
{
"name": "GNC-038",
"lang": "EN"
}
]
] | null |
NCT05789589 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-KOT-002"
]
},
{
"id_field": "acronym",
"id_value": [
"ADORATION"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2022-KOT-002"
]
}
] | https://clinicaltrials.gov/study/NCT05789589 | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases | To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled). | A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases | [
{
"description": "Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.<br/>All doses are... | [
{
"design_group_description": "In the Phase 1 portion of the study, three treatment regimens will be systematically evaluated:<br/>1. Azeliragon + SRS + loading corticosteroid dose (LD) + corticosteroid taper (CT)<br/>2. Azeliragon + SRS + loading corticosteroid dose (LD)<br/>3. Azeliragon + SRS<br/>The startin... | [
"Cancer",
"Metastasis",
"Metastatic Cancer",
"Brain Metastases",
"Brain Metastases, Adult"
] | [
"Baptist Health South Florida, Inc."
] | [
"Miami Cancer Institute, Inc.",
"Cantex Pharmaceuticals, Inc."
] | [
[
{
"name": "Azeliragon",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "558802255e5098e22d2e95952eee585e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ADORATION"
}
] |
NCT00829647 | [
{
"id_field": "org_study_id",
"id_value": [
"SCLL084993"
]
}
] | https://clinicaltrials.gov/study/NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Dasatinib and lenalidomide are both prescribed for use in patients with different cancers of the blood. This study is experimental because neither drug has been approved by the Food and Drug Administration for the treatment of chronic lymphocytic leukemia. There are few standard treatments when fludarabine is no longer... | A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia | [
{
"description": "dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po",
"name": "dasatinib and lenalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"spyrcel and revlimid"
],
"type": "Drug"
}
] | [
{
"design_group_description": "dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily",
"design_group_title": "combination dasatinib plus lenalidomide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Chronic Lymphocytic Leukemia",
"Leukemia"
] | [
"Scripps Health"
] | [
"Bristol Myers Squibb Co.",
"Celgene Corp."
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "达沙替尼",
"lang": "CN"
},
{
"name": "Dasatinib",
"lang": "EN"
},
{
"name"... | null |
NCT03858491 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-004290-28"
]
},
{
"id_field": "acronym",
"id_value": [
"OSIBOOST"
]
}
] | https://clinicaltrials.gov/study/NCT03858491 | Pharmacokinetic Boosting of Osimertinib | The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose. | Pharmacokinetic Boosting of Osimertinib in Patients With Non-small Cell Lung Cancer. | [
{
"description": "Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat wil... | [
{
"design_group_description": "Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).",
"... | [
"Non Small Cell Lung Cancer"
] | [
"Academisch Ziekenhuis Maastricht"
] | [
"Netherlands Cancer Insitute",
"ZonMw"
] | [
[
{
"name": "考比司他",
"lang": "CN"
},
{
"name": "Cobicistat",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2449828825dae2ad8308a4458e55a859",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "OSIBOOST"
}
] |
NCT00815646 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00003158"
]
}
] | https://clinicaltrials.gov/study/NCT00815646 | Prevention and Treatment of Immersion Pulmonary Edema | Immersion pulmonary edema (IPE) is a condition in which fluid fills the lungs during diving or swimming, particularly in cold water. Some individuals appear to be predisposed to developing IPE. DNA samples will be collected and stored, in order to compare the genetic profiles of individuals who have experienced IPE wit... | Effects of the Dive Reflex on Pulmonary Arterial and Pulmonary Artery Wedge Pressures in Subjects Who Have Experienced Immersion Pulmonary Edema | [
{
"description": "After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.",
"name": "Sildenafil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.",
"design_group_title": "Sildenafil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Immersion Pulmonary Edema (IPE)",
"Swimming Induced Pulmonary Edema (SIPE)"
] | [
"Duke University"
] | [
"Divers Alert Network (DAN)"
] | [
[
{
"name": "枸橼酸西地那非",
"lang": "CN"
},
{
"name": "Sildenaifl Citrate",
"lang": "EN"
},
{
"name": "シルデナフィルクエン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "84834e9e4da5e453ea3e95889d88a0e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NCT00815646"
}
] |
NCT04020419 | [
{
"id_field": "org_study_id",
"id_value": [
"1810087420"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2R01GM095657"
]
},
{
"id_field": "acronym",
"id_value": [
"Pediaberry"
]
}
] | https://clinicaltrials.gov/study/NCT04020419 | Natural Berry Extract Treatment of Hemangiomas | This is a prospective, randomized, double-blind, placebo-controlled parallel group study evaluating the use of PediaBerry for the treatment of hemangiomas in infants ≤ 4 months of corrected gestation age over a 6-month treatment period. Subjects will be followed to age 18 months. A total of 44 subjects will be PediaBer... | Natural Berry Extract Treatment of Hemangiomas | [
{
"description": "PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration",
"name": "PediaBerry",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"placebo"
],
"type": "Drug"
}
] | [
{
"design_group_description": "PediaBerry™ is a proprietary blend powdered berry extracts",
"design_group_title": "Pediaberry group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descri... | [
"Hemangioma"
] | [
"Indiana University"
] | [
"National Institute of General Medical Sciences",
"National Institutes of Health"
] | [
[
{
"name": "浆果提取物",
"lang": "CN"
},
{
"name": "Berry extract",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Pediaberry"
}
] |
NCT03815071 | [
{
"id_field": "org_study_id",
"id_value": [
"NSC-PD-YNYY-01"
]
}
] | https://clinicaltrials.gov/study/NCT03815071 | A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells | This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease | Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease | [
{
"description": "Total dose of ips-nsc cells will be administered at day0.",
"name": "Ips-nsc cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | [
{
"design_group_title": "ips-nsc treatment group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Total dose of ips-nsc cells will be administered at day0.",
"intervent... | [
"Parkinson Disease"
] | [
"Beijing Allife Medicine Technology Co., Ltd."
] | [
"Henan Provincial Peoples Hospital",
"Beijing Hospital of the Ministry of Health"
] | [
[
{
"name": "iPS-NSC cells(Allife Medical Science and Technology)",
"lang": "EN"
}
]
] | null |
NCT05126927 | [
{
"id_field": "org_study_id",
"id_value": [
"SN-2021-01"
]
}
] | https://clinicaltrials.gov/study/NCT05126927 | A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors | Primary objective To investigate the safety and tolerability profile of 68Ga- NODAGA-SNA006 in patients with solid tumors; To investigate the radiation absorbed dose characteristics of 68Ga-NODAGA-SNA006 in patients with solid tumors; To investigate the distribution profile of 68Ga-NODAGA-SNA006 in patients with solid ... | A Study to Evaluate the Safety Tolerability, Radiation Absorbed Dose,Distribution, PET Imaging and Histological Expression of 68GA-Nodaga-SNA006 in Patients With Solid Tumors. | [
{
"description": "A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors",
"name": "68Ga-NODAGA-SNA006",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors",
"design_group_title": "68Ga-NODAGA-SNA006",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Solid Tumor"
] | [
"Suzhou SmartNuclide Biopharmaceutical Co., Ltd."
] | [
"The First Affiliated Hospital of Soochow University"
] | [
[
{
"name": "68Ga-NODAGA-SNA006",
"lang": "EN"
}
]
] | null |
NCT00962845 | [
{
"id_field": "org_study_id",
"id_value": [
"0220090117"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA072720"
]
},
{
"id_domain": "NIH",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_valu... | https://clinicaltrials.gov/study/NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers.<br/>PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III or stage IV ... | A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma | [
{
"description": "200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enroll... | [
{
"design_group_description": "Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patie... | [
"Melanoma (Skin)"
] | [
"Rutgers State University of New Jersey"
] | [
"National Cancer Institute",
"Rutgers Cancer Institute of New Jersey"
] | [
[
{
"name": "硫酸羟氯喹",
"lang": "CN"
},
{
"name": "Hydroxychloroquine Sulfate",
"lang": "EN"
},
{
"name": "ドロキシクロロキン硫酸塩",
"lang": "JP"
}
]
] | null |
NCT06613490 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-SR-834"
]
}
] | https://clinicaltrials.gov/study/NCT06613490 | An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis | A single-center, open-label dose-escalation design to evaluate the safety and efficacy of 3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA); To evaluate the ability of KN550... | An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis | [
{
"description": "This study is a single-arm, open-label and single-center exploratory clinical study to evaluate the safety and effectiveness of anti CD19 CAR NK cells in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA). All subjects will receive fludarabine/cyclop... | [
{
"design_group_title": "anti CD19 CAR NK cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "This study is a single-arm, open-label and single-center exploratory clinical s... | [
"Antisynthetase Syndrome",
"Rheumatoid Arthritis"
] | [
"Third Affiliated Hospital of Nanjing Medical University"
] | [
"Rui Therapeutics Co., Ltd"
] | [
[
{
"name": "KN-5501",
"lang": "EN"
}
]
] | null |
NCT01239875 | [
{
"id_field": "org_study_id",
"id_value": [
"LS1081"
]
},
{
"id_domain": "NCI-CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2010-02003"
]
},
{
"id_domain": "Mayo Clinic Cancer Center & SPORE",
"id_field": "secondar... | https://clinicaltrials.gov/study/NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: ... | LS1081, "A Pilot Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation or Intradermally for Patients With B-Cell Non-Hodgkin's Lymphoma" | [
{
"description": "Given intratumorally",
"name": "dendritic cell vaccine therapy",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Undergo cryoablation",
"name": "cryotherapy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
... | [
{
"design_group_description": "Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.",
"design_group_title": "Arm A",
"design_group_type": "... | [
"Cutaneous B-cell Non-Hodgkin Lymphoma",
"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
"Nodal Marginal Zone B-cell Lymphoma",
"Adult Diffuse Mixed Cell Lymphoma",
"Adult Diffuse Small Cleaved Cell Lymphoma",
"Adult Grade III Lymphomatoid Granulomatosis",
"Adult Immunob... | [
"Mayo Clinic"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Autologous dendritic cell-tumor fusion vaccine(Mayo Clinic)",
"lang": "EN"
}
],
[
{
"name": "Autologous Dendritic Cells(Mayo Clinic)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LS1081"
}
] |
NCT06629428 | [
{
"id_field": "org_study_id",
"id_value": [
"H25013"
]
},
{
"id_field": "acronym",
"id_value": [
"U-PACE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"H25013"
]
}
] | https://clinicaltrials.gov/study/NCT06629428 | Effects of Ublituximab on Motor Functions in Multiple Sclerosis | The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status,... | Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People With Relapsing Multiple Sclerosis | [
{
"description": "The participants will receive 48 weeks of treatment with ublituximab.",
"name": "Ublituximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "This arm will receive a 48-week ublituximab treatment.",
"design_group_title": "Ublituximab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "... | [
"Multiple Sclerosis (MS) - Relapsing-remitting"
] | [
"Georgia State University"
] | [
"Atlanta Neuroscience Institute"
] | [
[
{
"name": "Ublituximab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "U-PACE"
}
] |
NCT05566600 | [
{
"id_field": "org_study_id",
"id_value": [
"JFYang"
]
}
] | https://clinicaltrials.gov/study/NCT05566600 | Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure | This study is designed to evaluate the safety and efficacy of allogeneic induced pluripotent cell derived cardiomyocytes (iPSC-CMs) in treating patients with worsening ischemic heart failure undergoing coronary artery bypass graft surgery.<br/>After screening, iPSC-CMs will be administrated intramyocardially in consent... | Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure | [
{
"description": "10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium",
"name": "Human (allogeneic) iPS-cell-derived cardiomyocyte",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "100 million iPSC-CMs administration",
"design_group_title": "Dose level 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "10-20 epicardial i... | [
"Ischemic Heart Failure",
"Chronic Heart Failure"
] | [
"Help Therapeutics Ltd."
] | [
"Central South University"
] | [
[
{
"name": "人iPSC来源心肌细胞（艾尔普）",
"lang": "CN"
},
{
"name": "iPSC derived cardiac muscle cell (Help Therapeutics)",
"lang": "EN"
}
]
] | null |
NCT01174056 | [
{
"id_field": "org_study_id",
"id_value": [
"DDCF-2010060"
]
}
] | https://clinicaltrials.gov/study/NCT01174056 | Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging | The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often pa... | Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone | [
{
"description": "600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation",
"name": "Zileuton",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zyflo"
],
"type": "Drug"
},
{
"description": "Lactose filled gelat... | [
{
"design_group_description": "Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days",
"design_group_title": "Pioglitazone+zileuton placebo",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Lung Inflammation"
] | [
"Washington University School of Medicine"
] | [
"Doris Duke Foundation"
] | [
[
{
"name": "盐酸吡格列酮",
"lang": "CN"
},
{
"name": "Pioglitazone Hydrochloride",
"lang": "EN"
},
{
"name": "ピオグリタゾン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "齐留通",
"lang": "CN"
},
{
"name": "Zileuton",
"lang": "EN"
}
]
... | null |
NCT02392039 | [
{
"id_field": "org_study_id",
"id_value": [
"2014-0880"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-00592"
]
}
] | https://clinicaltrials.gov/study/NCT02392039 | Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma | The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts). | Randomized, Placebo Controlled Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma | [
{
"description": "6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.",
"name": "Pegfilgrastim",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Neulasta",
"PEG-G-CSF"
],
"type": "Drug"
},
{
"descript... | [
{
"design_group_description": "Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.<br/>Cycle 1 and 3:<br/>Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.<br/>Cycle 2 and 4:<br... | [
"Lymphoma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Amgen, Inc."
] | [
[
{
"name": "氯雷他定",
"lang": "CN"
},
{
"name": "Loratadine",
"lang": "EN"
},
{
"name": "ロラタジン",
"lang": "JP"
}
]
] | null |
NCT07338604 | [
{
"id_field": "org_study_id",
"id_value": [
"PG-004-3"
]
}
] | https://clinicaltrials.gov/study/NCT07338604 | Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | This is a single-arm, open-label study designed to evaluate the safety, tolerability and cellular pharmacokinetic profiles of UTAA07 Injection. It also aims to preliminarily assess the efficacy of the investigational drug in subjects with relapsed/refractory hematolymphoid malignancies, so as to identify the optimal do... | Clinical Study of UTAA07 Injection in the Treatment of CD7 Positive Adult Relapsed/Refractory Hematologic and Lymphatic Systemic Malignancies | [
{
"description": "CAR-T cell infusion",
"name": "CAR-T cell infusion",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product that targets the CD7 antigen expressed on the s... | [
{
"design_group_title": "UTAA07 injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product th... | [
"Hematolymphoid Malignancies"
] | [
"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
] | [
"The First Affiliated Hospital of Soochow University"
] | [
[
{
"name": "UTAA-07",
"lang": "EN"
}
]
] | null |
NCT00657280 | [
{
"id_field": "org_study_id",
"id_value": [
"SU-04082008-1088"
]
},
{
"id_field": "acronym",
"id_value": [
"S-001"
]
}
] | https://clinicaltrials.gov/study/NCT00657280 | Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure | This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve ... | Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure | [
{
"description": "No one is blinded to the treatments.",
"name": "Sitagliptin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Januvia"
],
"type": "Drug"
}
] | [
{
"design_group_description": "All subjects are aware of what they are taking. Nobody is blinded in this study. study",
"design_group_title": "All subjects recieve Sitagliptin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervent... | [
"Heart Failure, Congestive"
] | [
"Stanford University"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "磷酸西格列汀",
"lang": "CN"
},
{
"name": "Sitagliptin Phosphate",
"lang": "EN"
},
{
"name": "シタグリプチンリン酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "995aa98825adea32485e29d8e5ee5005",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "S-001"
}
] |
NCT03445702 | [
{
"id_field": "org_study_id",
"id_value": [
"25319"
]
}
] | https://clinicaltrials.gov/study/NCT03445702 | Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I | Metformin is associated with a high degree of gastrointestinal intolerance, which limits the effective use of the medication. It is proposed to be an inhibitor of liver mitochondrial glycerophosphate dehydrogenase which results in partial blockade of mitochondrial complex 1 and inhibition of metabolism of lactate to py... | Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I | [
{
"description": "Metformin 1000mg once",
"name": "Metformin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Glucophage"
],
"type": "Drug"
},
{
"description": "Sugar pill manufactured to mimic metformin 1000mg",
"name": "Placebo",
"normalized_t... | [
{
"design_group_description": "Metformin 1000mg once",
"design_group_title": "Metformin intolerant & metformin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Metformin 10... | [
"Diabetes Mellitus, Type 2",
"Metformin Adverse Reaction"
] | [
"St. Louis University"
] | [
"Washington University School of Medicine"
] | [
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
"name": "メトホルミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT07071155 | [
{
"id_field": "org_study_id",
"id_value": [
"J2586"
]
},
{
"id_domain": "Johns Hopkins IRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IRB00509021"
]
},
{
"id_field": "acronym",
"id_value": [
"M-HArbOr"
]
}
] | https://clinicaltrials.gov/study/NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia | This research is being done to evaluate effectiveness, safety, and tolerability of a study drug called momelotinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), MDS/MPN-not otherwise specified (MDS/MPN-NOS), MDS/MPN with neutrophilia (MDS/MPN-N), also called as atypical chronic myeloid l... | A Pilot Study of Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (M-HArbOr) | [
{
"description": "Capsules of Momelotinib will be administered orally once a day by all participants for up to 24 months, depending on response to treatment.<br/>Dose escalation will include the first 3 patients who will receive either 150 mg or 200mg of momelotinib daily, depending on the number of dose limiti... | [
{
"design_group_description": "Combination of once daily oral momelotinib plus hypomethylating agents (HMA), e.g. azacitidine) starting cycle 1. Azacitidine will be administered as an injection at 75 mg/m2 for days 1-5 in a 28-day cycle.<br/>Dose escalation Phase:<br/>The first 3 patients will receive MMB 150 m... | [
"Chronic Myelomonocytic Leukemia",
"Myelodysplastic Syndromes",
"Myeloproliferative Overlap Neoplasms",
"Chronic Neutrophilic Leukemia"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"GSK Plc"
] | [
[
{
"name": "莫莫替尼",
"lang": "CN"
},
{
"name": "Momelotinib Dihydrochloride",
"lang": "EN"
},
{
"name": "モメロチニブ塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "阿扎胞苷",
"lang": "CN"
},
{
"name": "Azacitidine",
"lang": "EN"
}... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "M-HArbOr"
}
] |
NCT06541405 | [
{
"id_field": "org_study_id",
"id_value": [
"NK520-01"
]
}
] | https://clinicaltrials.gov/study/NCT06541405 | Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia | This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated. | An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia | [
{
"description": "The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.",
"name": "NK520",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"genetic modified NK ce... | [
{
"design_group_description": "NK520: 5x10^7 NK/kg",
"design_group_title": "Group A(low-dose group)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "The number of NK520 cel... | [
"Relapsed/Refractory Acute Myeloid Leukemia"
] | [
"Base Therapeutics (Shanghai) Ltd."
] | [
"Shanghai Children's Medical Center"
] | [
[
{
"name": "NK-520",
"lang": "EN"
}
]
] | null |
NCT06552260 | [
{
"id_field": "org_study_id",
"id_value": [
"24-339"
]
}
] | https://clinicaltrials.gov/study/NCT06552260 | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.<br/>The name of the study drug involved in this research study is:<br/>-Troriluzole (a tripeptide prodrug of riluzole) | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | [
{
"description": "Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.",
"name": "Troriluzole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-Amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide... | [
{
"design_group_description": "18 participants will be randomly assigned to this group and with complete:<br/>* Baseline visit with assessments and MRI.<br/>* Cycle 0:<br/> * Day -6 through Day 0: Predetermined dose of Troriluzole 2x daily.<br/> * Day 0: pre-op MRI<br/> * Day 0: standard of care surgical res... | [
"Glioblastoma",
"Recurrent Glioblastoma",
"Brain Tumor"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"Biohaven Pharmaceuticals, Inc.",
"National Institutes of Health"
] | [
[
{
"name": "Trigriluzole",
"lang": "EN"
}
]
] | null |
NCT02515240 | [
{
"id_field": "org_study_id",
"id_value": [
"HIV PPV23"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01AI081558"
]
}
] | https://clinicaltrials.gov/study/NCT02515240 | Immune Response to Pneumococcal Vaccination in HIV Infected Individuals | The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination. | Immune Response to Pneumococcal Vaccination in HIV Infected Individuals | [
{
"description": "23 valent pneumococcal polysaccharide vaccine in Healthy adults.",
"name": "PPV23",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"23 valent pneumococcal polysaccharide vaccine"
],
"type": "Biological"
}
] | [
{
"design_group_description": "healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.",
"design_group_title": "healthy controls",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention... | [
"Pneumococcal Infection"
] | [
"University of Toledo"
] | [
"National Institutes of Health"
] | [
[
{
"name": "23价肺炎球菌多糖疫苗 (北京科兴)",
"lang": "CN"
},
{
"name": "Pneumococcal 23-valent vaccine(Sinovac Biotech Ltd.)",
"lang": "EN"
}
]
] | null |
NCT03446651 | [
{
"id_field": "org_study_id",
"id_value": [
"2000022001"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01HL139629-01"
]
}
] | https://clinicaltrials.gov/study/NCT03446651 | Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure | The purpose of this study is to understand the effects of chloride supplementation on volume-overloaded acute heart failure patients concomitantly treated with IV diuretics. | Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure | [
{
"description": "Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride & the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the ... | [
{
"design_group_description": "Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.",
"design_group_title": "Lysine Chloride",
"design_group_type": "Experimental",
"desig... | [
"Heart Failure"
] | [
"Yale University"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "盐酸赖氨酸",
"lang": "CN"
},
{
"name": "L-Lysine hydrochloride",
"lang": "EN"
}
]
] | null |
NCT03145259 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00067047"
]
}
] | https://clinicaltrials.gov/study/NCT03145259 | Evaluation of Bioavailability of Diclofenac Dermal Products | The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations. | Evaluation of Bioavailability of Diclofenac Dermal Products | [
{
"description": "patch",
"name": "Diclofenac Epolamine Patch",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"patch"
],
"type": "Drug"
},
{
"description": "solution",
"name": "diclofenac sodium solution",
"normalized_type": "3d1aa88261d64c03841... | [
{
"design_group_description": "Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]",
"design_group_title": "Diclofenac patch",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "patch",
"intervention_name": "Diclofenac Epolamine ... | [
"Bioavailability"
] | [
"University of Maryland Baltimore"
] | [
"US Food & Drug Administration"
] | [
[
{
"name": "双氯芬酸依泊胺",
"lang": "CN"
},
{
"name": "Diclofenac Epolamine",
"lang": "EN"
}
],
[
{
"name": "双氯芬酸钠",
"lang": "CN"
},
{
"name": "Diclofenac Sodium",
"lang": "EN"
},
{
"name": "ジクロフェナクナトリウム",
"lang": "JP"
... | null |
NCT02239354 | [
{
"id_field": "org_study_id",
"id_value": [
"VC01-101"
]
}
] | https://clinicaltrials.gov/study/NCT02239354 | A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus | The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is an effective treatment for subjects with Type 1 Diabetes. | A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus | [
{
"description": "Biologic and Device",
"name": "VC-01™ Combination Product",
"normalized_type": "26823d77f12d4744a960c336f01c2d6e",
"type": "Combination Product"
}
] | [
{
"design_group_description": "2 VC-01™ Combination Product implants",
"design_group_title": "Cohort 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Biologic and Device"... | [
"Type 1 Diabetes Mellitus"
] | [
"ViaCyte, Inc."
] | [
"California Institute for Regenerative Medicine"
] | [
[
{
"name": "PEC Encap",
"lang": "EN"
}
]
] | null |
NCT03008187 | [
{
"id_field": "org_study_id",
"id_value": [
"CLI24-001"
]
},
{
"id_field": "acronym",
"id_value": [
"Diamond-01"
]
}
] | https://clinicaltrials.gov/study/NCT03008187 | MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia | The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML). | A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia | [
{
"description": "MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.",
"name": "MEN1703",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SEL24",
"SEL24-B489"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants received MEN1703 (25 milligrams [mg]) orally once daily for 14 consecutive days in cycles of 21 days.",
"design_group_title": "Cohort 1 (25 mg)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Acute Myeloid Leukemia"
] | [
"A.Menarini Industrie Farmaceutiche Riunite Srl"
] | [
"Theradex (Europe) Ltd.",
"Medpace, Inc."
] | [
[
{
"name": "Dapolsertib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "339053300e5e48d2a25e055933a4522d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "52ed8e22a420a5ad0889829dae330522",
"s... |
NCT01518556 | [
{
"id_field": "org_study_id",
"id_value": [
"AML-2011-01"
]
},
{
"id_field": "acronym",
"id_value": [
"IDAML"
]
}
] | https://clinicaltrials.gov/study/NCT01518556 | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia | The purpose of this study is to determine whether idarubicin dose intensification is safe and effective as a remission induction therapy for acute myeloid leukemia. | Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less | [
{
"description": "In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.<br/>In the phase II study, idarubicin dose is the maximum tolerated dose that is deter... | [
{
"design_group_description": "Idarubicin dose intensification for remission induction in acute myeloid leukemia",
"design_group_title": "Idarubicin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"in... | [
"Leukemia, Myeloid, Acute"
] | [
"Konkuk University Medical Center"
] | [
"Jeonbuk National University Hospital",
"Samsung Medical Center",
"Seoul National University Hospital",
"Soon Chun Hyang University",
"Pusan National University Hospital",
"Ewha Womans University",
"Chung-Ang University Hosptial"
] | [
[
{
"name": "盐酸伊达比星",
"lang": "CN"
},
{
"name": "Idarubicin Hydrochloride",
"lang": "EN"
},
{
"name": "イダルビシン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IDAML"
}
] |
NCT00834678 | [
{
"id_field": "org_study_id",
"id_value": [
"OSU-08164"
]
},
{
"id_domain": "Clinical Trial Reporting Program (CTRP)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-03164"
]
}
] | https://clinicaltrials.gov/study/NCT00834678 | Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumo... | Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer | [
{
"description": "100 or 120 mg/m2 IV on days 1 and 2",
"name": "bendamustine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ribomustin",
"SDX- 105",
"Treanda"
],
"type": "Drug"
},
{
"description": "100 or 150 mg po on days 5 - 21 of each ... | [
{
"design_group_description": "Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.",
"design_group_title": "Bendamustine and Erlotinib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Breast Cancer"
] | [
"Ohio State University Comprehensive Cancer Center"
] | [
"Genentech, Inc.",
"National Comprehensive Cancer Network, Inc."
] | [
[
{
"name": "盐酸苯达莫司汀",
"lang": "CN"
},
{
"name": "Bendamustine Hydrochloride",
"lang": "EN"
},
{
"name": "ベンダムスチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lan... | null |
NCT05240300 | [
{
"id_field": "org_study_id",
"id_value": [
"BMX-05-001"
]
}
] | https://clinicaltrials.gov/study/NCT05240300 | A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis | The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD). | A Phase 1b/2a, Double-blind (Sponsor Open), Randomized, Vehicle-controlled Study of Topically Administered BX005-A in Subjects With Moderate to Severe Atopic Dermatitis | [
{
"description": "phage gel",
"name": "BX005-A",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "vehicle gel",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | [
{
"design_group_description": "twice daily topical application x 8 weeks",
"design_group_title": "BX005-A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "phage gel",
... | [
"Atopic Dermatitis"
] | [
"BiomX, Inc."
] | [
"Maruho Co., Ltd."
] | [
[
{
"name": "BX-005",
"lang": "EN"
}
]
] | null |
NCT00867321 | [
{
"id_field": "org_study_id",
"id_value": [
"NCCTG-N0745"
]
},
{
"id_domain": "CTRP (Clinical Trials Reporting System)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2009-01178"
]
},
{
"id_domain": "PDQ (Physician Data Query... | https://clinicaltrials.gov/study/NCT00867321 | Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes ne... | Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma | [
{
"description": "Given IV",
"name": "bevacizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Given orally",
"name": "sorafenib tosylate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.",
"design_group_title": "Arm I (Phase II)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervent... | [
"Liver Cancer"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute"
] | [
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ベバシズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
... | null |
NCT00307736 | [
{
"id_field": "org_study_id",
"id_value": [
"05-345"
]
}
] | https://clinicaltrials.gov/study/NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II portion) patients wi... | A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer | [
{
"description": "Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.",
"name": "5-fluorouracil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Given intravenously on day 1 of each 14-day cycle for a total of 3 c... | [
{
"design_group_description": "Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.",
"design_group_title": "Chemotherapy and radiation",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "... | [
"Rectal Cancer",
"Adenocarcinoma of the Rectum"
] | [
"The General Hospital Corp."
] | [
"Genentech, Inc.",
"Dana-Farber Cancer Institute, Inc.",
"Beth Israel Deaconess Medical Center, Inc."
] | [
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lang": "EN"
},
{
"name": "エルロチニブ塩酸塩",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
... | null |
NCT06110793 | [
{
"id_field": "org_study_id",
"id_value": [
"23-274"
]
}
] | https://clinicaltrials.gov/study/NCT06110793 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer. | A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer | [
{
"description": "20mg orally PO daily",
"name": "Lenvatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "400mg IV Q6W",
"name": "Pembrolizuma",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"des... | [
{
"design_group_description": "This is an open-label phase Ib/II trial of lenvatinib (20mg orally PO daily) plus pembrolizumab (400mg IV Q6W) plus fulvestrant (500mg IM Q4W) in patients with unresectable, locally advanced/metastatic ER+/HER2- breast cancer.",
"design_group_title": "Lenvatinib, Pembrolizumab... | [
"Metastatic Breast Cancer"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "氟维司群",
"lang": "CN"
},
{
"name": "Fulvestrant",
"lang": "EN"
},
{
"name": "フルベストラント",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"n... | null |
NCT07288814 | [
{
"id_field": "org_study_id",
"id_value": [
"CSPC-DED-PTCL-K08"
]
}
] | https://clinicaltrials.gov/study/NCT07288814 | Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | To evaluate the safety of mitoxantrone hydrochloride liposome combined with enlonstobart in the treatment of relapsed or refractory peripheral T-cell lymphoma, to determine the optimal dosage of mitoxantrone hydrochloride liposome within the combination regimen, and to assess the efficacy of the combined therapy. | A Single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma（PTCL） | [
{
"description": "Mitoxantrone hydrochloride liposome: ①Phase Ib：16 mg/m2、20 mg/m2 ，D1，q4w; ②Phase II：RP2D, D1，q4w, Up to 6 cycles<br/>Enlonstobart: 360mg，D1，q4w (The maintenance treatment phase is q3w), Up to 1 year",
"name": "Mitoxantrone Hydrochloride Liposome & Enlonstobart",
"normalized_type": "3d1... | [
{
"design_group_title": "Mitoxantrone hydrochloride liposome combined with enlonstobart",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Mitoxantrone hydrochloride liposome: ①P... | [
"Relapsed or Refractory Peripheral T Cell Lymphoma"
] | [
"Sun Yat-Sen University Cancer Center"
] | [
"CSPC Ouyi Pharmaceutical Co., Ltd."
] | [
[
{
"name": "恩朗苏拜单抗",
"lang": "CN"
},
{
"name": "Enlonstobart",
"lang": "EN"
}
],
[
{
"name": "盐酸米托蒽醌脂质体",
"lang": "CN"
},
{
"name": "Mitoxantrone Hydrochloride liposomal",
"lang": "EN"
}
]
] | null |
NCT05674656 | [
{
"id_field": "org_study_id",
"id_value": [
"205868"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2022-000829-24"
]
}
] | https://clinicaltrials.gov/study/NCT05674656 | Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics | The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to less than 12 years of ag... | Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1 | [
{
"description": "Dolutegravir/Rilpivirine will be administered.",
"name": "Dolutegravir/Rilpivirine FDC",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"JULUCA"
],
"type": "Drug"
}
] | [
{
"design_group_title": "Dolutegravir(DTG)/Rilpivirine (RPV)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dolutegravir/Rilpivirine will be administered.",
"interven... | [
"HIV Infections"
] | [
"ViiV Healthcare Ltd."
] | [
"Janssen Research & Development LLC"
] | [
[
{
"name": "多替拉韦利匹韦林",
"lang": "CN"
},
{
"name": "Dolutegravir Sodium/Rilpivirine Hydrochloride",
"lang": "EN"
},
{
"name": "ドルテグラビルナトリウム/リルピビリン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT02022670 | [
{
"id_field": "org_study_id",
"id_value": [
"R21HL107105"
]
}
] | https://clinicaltrials.gov/study/NCT02022670 | Sodium Nitrite to Treat Arterial Aging | The proposed research will determine the effectiveness of nitrite, a naturally occurring compound in the body, for improving the health and function of arteries in middle-aged and older adults. The study also will provide insight into how sodium nitrite therapy improves artery health by determining the physiological me... | Clinical Translation of Nitrite Therapy to Treat Arterial Aging in Humans | [
{
"description": "Sugar pill manufactured to mimic sodium nitrite capsules",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "80 mg/d or 160 mg/d",
"name": "Sodium Nitrite",
"normalized_type": "3d1aa88261d64c038413723970f2b... | [
{
"design_group_description": "inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
... | [
"Vascular Aging"
] | [
"University of Colorado Boulder"
] | [
"TheraVasc, Inc."
] | [
[
{
"name": "Sodium nitrite",
"lang": "EN"
}
]
] | null |
NCT02265731 | [
{
"id_field": "org_study_id",
"id_value": [
"M13-834"
]
}
] | https://clinicaltrials.gov/study/NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies. | A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies | [
{
"description": "75 mg/m2 by IV infusion or subcutaneous dosing",
"name": "azacitadine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Step-up doses of venetoclax to the designated cohort dose",
"name": "venetoclax",
"normalized_type": "3... | [
{
"design_group_description": "Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)",
"design_group_title": "Arm A (Phase 1)",
"design_group_type": "Experimental",
"design_group_ty... | [
"Non-Hodgkin Lymphoma (NHL)",
"Multiple Myeloma (MM)",
"Chronic Lymphocytic Leukemia (CLL)",
"Small Lymphocytic Lymphoma (SLL)",
"Acute Myeloid Leukemia (AML)"
] | [
"AbbVie, Inc."
] | [
"Genentech, Inc."
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "利妥昔单抗",
"lang": "CN"
},
{
"name": "Rituximab",
"lang": "EN"
},
{
"name": "... | [
{
"identifier_source": [
{
"code": "25a4954949533a82e0d5400205888092",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PB1890"
}
] |
NCT07432633 | [
{
"id_field": "org_study_id",
"id_value": [
"BED-FAP-121"
]
}
] | https://clinicaltrials.gov/study/NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithe... | A Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | [
{
"description": "positron emission tomography (PET)/computed tomography (CT) imaging",
"name": "[18F]FPyQCP",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Each participant will receive [18F]FPyQCP followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2)",
"design_group_title": "[18F]FPyQCP PET/CT",
"design_group_type": "Experimental",
"design_group_type_normali... | [
"Colorectal Cancer",
"Epithelial Ovarian Cancer",
"Gastric Cancer",
"Invasive Lobular Breast Carcinoma",
"Pancreatic Ductal Adenocarcinoma"
] | [
"Blue Earth Diagnostics Ltd."
] | [
"Medpace, Inc."
] | [
[
{
"name": "[18F]-FPyQCP",
"lang": "EN"
}
]
] | null |
NCT05109559 | [
{
"id_field": "org_study_id",
"id_value": [
"VAC31518COV2012"
]
}
] | https://clinicaltrials.gov/study/NCT05109559 | Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine | This study aims to address evidence gaps regarding the safety, reactogenicity and immune responses of a heterologous boost of a single dose of Ad26.COV2.S (half or full dose) at pre-specified time intervals in recipients who are documented to have received either 1-dose or 2-doses (primary series completion) of inactiv... | A Phase 1/2 Study to Evaluate the Safety Reactogenicity and Immunogenicity of Ad26.COV2.S Administered as a Heterologous Booster Vaccination in Adults 18 Years of Age and Older Following Single- or Two-Dose Vaccination With an Inactivated COVID-19 Vaccine | [
{
"description": "A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.",
"name": "Full dose of Ad26.COV2. 5x10^10vp",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "A booster dose (3rd dose) of Ad26.COV... | [
{
"design_group_description": "Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days ... | [
"SARS-CoV-2 Infection"
] | [
"Mahidol University"
] | [
"International Vaccine Institute",
"Janssen Pharmaceuticals, Inc.",
"National Vaccine Institute"
] | [
[
{
"name": "COVID-19 Vaccine(Janssen)",
"lang": "EN"
},
{
"name": "コロナウイルス（SARS-CoV-2）ワクチン（遺伝子組換えアデノウイルスベクター）(Janssen)",
"lang": "JP"
}
]
] | null |
NCT04713046 | [
{
"id_field": "org_study_id",
"id_value": [
"J21112"
]
},
{
"id_domain": "JHM IRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IRB00244082"
]
}
] | https://clinicaltrials.gov/study/NCT04713046 | Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers | In this study, haploidentical relatives of a patient with recurrent or metastatic HPV 16-associated malignancy will be vaccinated with a therapeutic human papillomavirus (HPV) vaccine series to generate HPV-specific leukocytes. The cancer patient with recurrent or metastatic HPV16+ cancer will then be randomized to one... | A Phase I Clinical Trial Assessing the Safety, Feasibility and Immunologic Correlates of Allogeneic HPV-specific Cluster of Differentiation 4 (CD4)+ T Cells in Advanced HPV16-associated Malignancies | [
{
"description": "Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10^6 CD4+ cells/kg; 2) 5 x 10^6 CD4+ cells/kg; or 3) 10^7 CD4+ cells/kg of recipient ideal body weight.",
"name": "CD8 reduced peripheral blood cells taken from rela... | [
{
"design_group_description": "non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.",
"design_group_title": "Allogeneic bone marrow transplant",
"design_group_type": "Experimental",
"design_group_type_normal... | [
"HPV 16+ Recurrent or Metastatic Cancer"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"Papivax Biotech, Inc."
] | [
[
{
"name": "ISA-101",
"lang": "EN"
}
]
] | null |
NCT02558816 | [
{
"id_field": "org_study_id",
"id_value": [
"RC14_0048"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-003740-13"
]
},
{
"id_field": "acronym",
"id_value": [
"OAsIs"
]
}
] | https://clinicaltrials.gov/study/NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | This is an open label, multicenter, fixed dose and dose escalation, phase I/II study.<br/>The study will be conducted in 3 steps. The first one (step A) will be to ensure the safety of the combination of Obinutuzumab (GA101) and Ibrutinib at fixed doses in patients with relapsed or refractory Mantle Cell Lymphoma (MCL)... | A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients | [
{
"description": "Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199",
"name": "Ibrutinib + GA101 +GDC-0199",
"normalized_type... | [
{
"design_group_description": "STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibr... | [
"Mantle Cell Lymphoma"
] | [
"Nantes University Hospital"
] | [
"Roche Pharma AG",
"Janssen LP"
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
],
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e8e92ee8e222ed022a5392e9452d088",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8552230a9a288a5552e489d330232458",
"s... |
NCT01160354 | [
{
"id_field": "org_study_id",
"id_value": [
"2009-0536"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2012-01786"
]
}
] | https://clinicaltrials.gov/study/NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | The goal of Part 1 of this clinical research study is to learn about the safety of the combination of plerixafor and clofarabine when given to patients with previously untreated AML who are at least 60 years old.<br/>The goal of Part 2 of this study is to learn if the combination of plerixafor and clofarabine can help ... | Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit | [
{
"description": "Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine",
"name": "Plerixafor",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mobozil"
],
"type": "Drug"... | [
{
"design_group_description": "Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).<br/>Phase II: Plerixafor at the highest dose tolerated in Phase I.<... | [
"Acute Myelogenous Leukemia"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Genzyme Corp."
] | [
[
{
"name": "氯法拉滨",
"lang": "CN"
},
{
"name": "Clofarabine",
"lang": "EN"
},
{
"name": "クロファラビン",
"lang": "JP"
}
],
[
{
"name": "普乐沙福",
"lang": "CN"
},
{
"name": "Plerixafor",
"lang": "EN"
},
{
"name": ... | null |
NCT07281976 | [
{
"id_field": "org_study_id",
"id_value": [
"LBL-024-CN005"
]
},
{
"id_field": "secondary_id",
"id_value": [
"LBL-024-CN005"
]
}
] | https://clinicaltrials.gov/study/NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC). | An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer | [
{
"description": "Intravenous infusion.",
"name": "LBL-024 for Injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LBL-024"
],
"type": "Drug"
},
{
"description": "Intravenous infusion.",
"name": "albumin-bound Paclitaxel injection",
"norm... | [
{
"design_group_description": "Experimental group：<br/>LBL-024 + albumin-bound paclitaxel.<br/>Intravenous infusion.",
"design_group_title": "LBL-024 + albumin-bound paclitaxel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"Triple Negative Breast Cancer"
] | [
"Nanjing Leads Biolabs Co., Ltd."
] | [
"Third Affiliated Hospital of Nanjing Medical University"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "奥帕替苏米单抗",
"lang": "CN"
},
{
"name": "Opamtistomig",
"lang": "EN"... | null |
NCT05522192 | [
{
"id_field": "org_study_id",
"id_value": [
"CSPC-DED-AML-K04"
]
}
] | https://clinicaltrials.gov/study/NCT05522192 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | This study is an open-label, single-arm, phase I/II clinical study. Phase I is a multi-center, dose-escalation study, aiming to explore the maximum tolerated dose (MTD) of venetoclax combined with mitoxantrone liposome in the treatment of relapsed or refractory acute myeloid leukemia (AML), and determine the recommende... | Clinical Study of Venetoclax Combined With Mitoxantrone Liposome in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | [
{
"description": "Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.",
"name": "Mitoxantrone liposome",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mitoxantrone Hydrochloride Liposome Injection"
],
"type": "Drug"
},
{
"description": "Phase ... | [
{
"design_group_description": "Phase I<br/>Mitoxantrone liposome<br/>* Level 1: 24mg/m^2, ivgtt, d1;<br/>* Level 2: 30mg/m^2, ivgtt, d1;<br/>* Level 3: 36mg/m^2, ivgtt, d1;<br/>Venetoclax: 100mg po d1, 200mg po d2, 400mg po d3-28.<br/>Every 4 weeks is a cycle, a total of 2 cycles, the first cycle to observe DLT... | [
"Relapsed or Refractory Acute Myeloid Leukemia"
] | [
"The First Affiliated Hospital of Jinan University"
] | [
"CSPC Ouyi Pharmaceutical Co., Ltd."
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "盐酸米托蒽醌脂质体",
"lang": "CN"
},
{
"name": "Mitoxantrone Hydrochloride liposomal",
"lang": "E... | null |
NCT04083183 | [
{
"id_field": "org_study_id",
"id_value": [
"RG1005632"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-05727"
]
},
{
"id_domain": "Fred Hutch / University of ... | https://clinicaltrials.gov/study/NCT04083183 | Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases | This phase I/II trial studies the best dose of total body irradiation with astatine-211 BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases undergoing hematopoietic cell transplant. Radiation therapy uses high energy gamma rays to kill cancer cells and shrink tumors. Astatine-211-labele... | Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases | [
{
"description": "Given IV",
"name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"APAMISTAMAB-B10-ASTATINE AT-211",
"Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10",
"Astatine At 211 MAb... | [
{
"design_group_description": "Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on... | [
"Non-Malignant Neoplasm"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | null |
NCT05512988 | [
{
"id_field": "org_study_id",
"id_value": [
"TongjiHospitalxugangtjh"
]
}
] | https://clinicaltrials.gov/study/NCT05512988 | Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 ) | The chronic kidney disease is caused by renal structural and functional impairment for more than 3 months due to various causes, including normal and abnormal glomerular filtration rate (GFR), abnormal blood, urine, and imaging findings, or an unexplained decline in GFR (<60 ml/min). Recent years, the incidence of chro... | A Randomized, Double-blind, Controlled Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 ) | [
{
"description": "Usage: The stem cell preparation in this study is used intravenously in the elbow.<br/>Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection, and the injection frequency is 2 weeks/time.<br/>Duration: 2 injections per trial group for the entire dur... | [
{
"design_group_description": "MSCs Participants will receive HUC-MSCs",
"design_group_title": "Experimental",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Usage: The ste... | [
"Chronic Kidney Diseases"
] | [
null
] | [
null
] | [
[
{
"name": "Human Umbilical Cord Mesenchymal Stem Cells(Zhongyuan Union Stem Cell Bioengineering Co., Ltd.)",
"lang": "EN"
}
]
] | null |
NCT03975907 | [
{
"id_field": "org_study_id",
"id_value": [
"CT053-MM-01"
]
}
] | https://clinicaltrials.gov/study/NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma. | Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | [
{
"description": "The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.",
"name": "CAR-BCMA T Cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm",
"design_group_title": "CAR-BCMA T Cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Multiple Myeloma"
] | [
"CARsgen Therapeutics Co. Ltd."
] | [
"Beijing Chao-Yang Hospital",
"The Third Xiangya Hospital of Central South University",
"Qilu Hospital of Shandong University",
"Xinhua Hospital",
"the First Affiliated Hospital of Sun Yat-Sen University",
"The First Affiliated Hospital, Zhejiang University Sch of Med",
"The First Affiliated Hospital of... | [
[
{
"name": "泽沃基奥仑赛",
"lang": "CN"
},
{
"name": "Zevorcabtagene Autoleucel",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "ea5255002a3ae4d2284505d4280a9a5a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "LUMMICAR STUDY1"
},
{
"identifier_source": [
{
"code": "2e4039e9e590e828e23a88230a225585",
"source": "CT_... |
NCT02553460 | [
{
"id_field": "org_study_id",
"id_value": [
"TINI"
]
},
{
"id_domain": "NCI Clinical Trial Registration Program",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-01493"
]
}
] | https://clinicaltrials.gov/study/NCT02553460 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, but it could ... | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | [
{
"description": "Given intrathecally (IT).",
"name": "ITMHA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Intrathecal Triples",
"Methotrexate/hydrocortisone/cytarabine"
],
"type": "Drug"
},
{
"description": "Given orally (PO) or naso-gastrical... | [
{
"design_group_description": "Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.<br/>Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, v... | [
"Acute Lymphoblastic Leukemia"
] | [
"St. Jude Children's Research Hospital, Inc."
] | [
"Gateway for Cancer Research",
"Baylor College of Medicine"
] | [
[
{
"name": "伏立诺他",
"lang": "CN"
},
{
"name": "Vorinostat",
"lang": "EN"
},
{
"name": "ボリノスタット",
"lang": "JP"
}
],
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エ... | null |
NCT02058017 | [
{
"id_field": "org_study_id",
"id_value": [
"NP01/27/13"
]
},
{
"id_domain": "NHG Domain Specific Review Board",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2013/00691"
]
}
] | https://clinicaltrials.gov/study/NCT02058017 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | This is a lead-in dose escalation study to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), and recommended Phase II dose of OPB-51602 administered on a weekly basis in subjects with advanced malignancies. Using the recommended phase II dose, the efficacy and tolerability of OPB-51602... | The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal C... | [
{
"name": "OPB-51602",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"OPB-51602 OPB-51602 is an inhibitor of STAT3 phosphorylation developed by Otsuka Pharmaceuticals, Japan."
],
"type": "Drug"
}
] | [
{
"design_group_description": "Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.<br/>Part II - This... | [
"Nasopharyngeal Carcinoma"
] | [
"National University Hospital"
] | [
"Otsuka Pharmaceutical Co., Ltd.",
"Shin Nippon Biomedical Laboratories, Ltd."
] | [
[
{
"name": "OPB-51602",
"lang": "EN"
}
]
] | null |
NCT04493151 | [
{
"id_field": "org_study_id",
"id_value": [
"59752"
]
}
] | https://clinicaltrials.gov/study/NCT04493151 | Imipenem/Cilastatin/Relebactam PK in ECMO | Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may e... | Pharmacokinetics of Imipenem/Cilastatin/Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) | [
{
"description": "After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.",
"name": "Imipenem, Cilastatin and Relebactam",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Recarbri... | [
{
"design_group_description": "Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.",
"design_group_title": "Imipenem-Cilastatin-Relebactam",
"design_group_type": "Experimental",
"d... | [
"Sepsis"
] | [
"Hartford Hospital"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "西司他丁/亚胺培南/瑞来巴坦",
"lang": "CN"
},
{
"name": "Cilastatin Sodium/Imipenem/Relebactam",
"lang": "EN"
},
{
"name": "レレバクタム水和物/イミペネム水和物/シラスタチンナトリウム",
"lang": "JP"
}
]
] | null |
NCT00627679 | [
{
"id_field": "org_study_id",
"id_value": [
"MAP0010-CL-P101"
]
},
{
"id_field": "acronym",
"id_value": [
"UDB P101"
]
}
] | https://clinicaltrials.gov/study/NCT00627679 | Safety and Blood Level Study of Unit Dose Budesonide | The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers. | A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 | [
{
"description": "Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.",
"name": "Budesonide Inhalation Suspension",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pulmic... | [
{
"design_group_description": "Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatme... | [
"Asthma"
] | [
"Allergan UC"
] | [
"Q-Pharm Pty Ltd.",
"MAP Pharmaceuticals LLC"
] | [
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "3822de252e8a25ae2e452002385508ae",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "UDB P101"
}
] |
NCT01522378 | [
{
"id_field": "org_study_id",
"id_value": [
"11-006296"
]
}
] | https://clinicaltrials.gov/study/NCT01522378 | Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging | Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen i... | Cardiac Resynchronization and MIBG Imaging | [
{
"description": "10 millicurie (mCi) (370 MBq)",
"name": "123 iodine metaiodobenzylguanidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"AdreView"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects will be imaged with 123 iodine metaiodobenzylguanidine.",
"design_group_title": "Biv-ICD",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descripti... | [
"Congestive Heart Failure"
] | [
"Mayo Clinic"
] | [
"GE Healthcare Holdings, Inc."
] | [
[
{
"name": "碘[123I]苄胍",
"lang": "CN"
},
{
"name": "Iobenguane I-123",
"lang": "EN"
},
{
"name": "3-ヨードベンジルグアニジン（123I）",
"lang": "JP"
}
]
] | null |
NCT04689048 | [
{
"id_field": "org_study_id",
"id_value": [
"2019-KOT-001"
]
}
] | https://clinicaltrials.gov/study/NCT04689048 | Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery | The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will l... | Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery | [
{
"description": "Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine... | [
{
"design_group_description": "In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted... | [
"Brain Metastases, Adult",
"Brain Metastases",
"Brain Cancer"
] | [
"Baptist Health South Florida, Inc."
] | [
"Blue Earth Diagnostics Ltd."
] | [
[
{
"name": "[18F]氟氨基丁酸",
"lang": "CN"
},
{
"name": "Fluciclovine 18F",
"lang": "EN"
},
{
"name": "フルシクロビン（18F）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2320a39a5d5aadead2208220284202a4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Phase 1 Proof-of-Concept Interim Analysis"
}
] |
NCT06889493 | [
{
"id_field": "org_study_id",
"id_value": [
"20231325"
]
}
] | https://clinicaltrials.gov/study/NCT06889493 | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | The purpose of this study is to determine:<br/>1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.<br/>2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.<br/>3. The highest dose and freq... | A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors | [
{
"description": "SVV-001 will be administered intratumorally as a single dose on Day 1; or as multiple doses on Days 1, 15, 29, 43, 57, and 71. The virus dose levels per SVV-001 treatment are as follows:<br/>* 2.2 × 10^8 Viral Genomes (VG) (starting dose)<br/>* 2.2 × 10^9 VG<br/>* 2.2 × 10^10 VG",
"name": ... | [
{
"design_group_description": "Participants in this group will receive a single dose of SVV-001 on Day 1, in combination with Nivolumab and Ipilimumab therapy.<br/>Total participation duration is up to 2 years.",
"design_group_title": "SVV-001 Single Dose Treatment Group",
"design_group_type": "Experime... | [
"Neuroendocrine Carcinoma",
"Neuroendocrine Tumors"
] | [
"University of Miami"
] | [
"Seneca Therapeutics, Inc."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT03403595 | [
{
"id_field": "org_study_id",
"id_value": [
"PekingUMCH-NM16"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"ZIAEB000073"
]
}
] | https://clinicaltrials.gov/study/NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using 177Lu-EB-PSMA-617. All patients underwent whole-body 68Ga-PSMA P... | Safety and Dosimetry of 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | [
{
"description": "accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.",
"name": "177Lu-EB-PSMA-617",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.",
"design_group_title": "177Lu-EB-PSMA-617 dosimetry calculation",
"design_group_type": "Experimental",
... | [
"Metastatic Castration-resistant Prostate Cancer"
] | [
"Peking Union Medical College Hospital"
] | [
"National Institute For Biomedical Imaging And Bioengineering (Nibib)"
] | [
[
{
"name": "177Lu-EB-PSMA-617(National Institute For Biomedical Imaging And Bioengineering (Nibib))",
"lang": "EN"
}
]
] | null |
NCT02837263 | [
{
"id_field": "org_study_id",
"id_value": [
"UW15063"
]
},
{
"id_domain": "NCI Trial ID",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-01077"
]
},
{
"id_domain": "Institutional Review Board",
"id_field": "secondary_... | https://clinicaltrials.gov/study/NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | The purpose of this research study is:<br/>* To find out how safe the study drug, pembrolizumab, is when combined with stereotactic body radiotherapy (SBRT) to the liver.<br/>* To see how well subjects can tolerate treatment with pembrolizumab and SBRT.<br/>* To find out how often colorectal cancer comes back 1 year af... | Pembrolizumab in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | [
{
"description": "SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.<br/>SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed ... | [
{
"design_group_description": "Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic diseas... | [
"Colorectal Cancer",
"Colorectal Adenocarcinoma",
"Stage IVA Colorectal Cancer",
"Stage IVB Colorectal Cancer",
"Metastatic Carcinoma in the Liver"
] | [
"University of Wisconsin-Madison"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02446964 | [
{
"id_field": "org_study_id",
"id_value": [
"14106"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-00788"
]
},
{
"id_field": "secondary_id",
"id_value": [... | https://clinicaltrials.gov/study/NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | This phase I trial studies the side effects and best dose of total bone marrow and lymphoid irradiation when given together with chemotherapy before donor stem cell transplant in treating patients with myelodysplastic syndrome or acute leukemia. Total marrow and lymphoid irradiation is a type of radiation therapy that ... | Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia | [
{
"description": "Undergo bone marrow transplant",
"name": "Bone Marrow Transplantation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"BMT",
"Bone Marrow Grafting",
"Bone Marrow Transplant",
"Marrow Transplantation"
],
"type": "Procedure"
... | [
{
"design_group_description": "CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.<br/>TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cel... | [
"Adult Acute Lymphoblastic Leukemia in Complete Remission",
"Acute Myeloid Leukemia in Remission",
"Previously Treated Myelodysplastic Syndrome",
"Recurrent Adult Acute Lymphoblastic Leukemia",
"Recurrent Adult Acute Myeloid Leukemia",
"Recurrent Childhood Acute Lymphoblastic Leukemia",
"Recurrent Child... | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | [
{
"identifier_source": [
{
"code": "0a28e92923ad5858854229529ed9ead2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "3d4228224952a8825ea2d8a05a5e5253",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "O05... |
NCT03440567 | [
{
"id_field": "org_study_id",
"id_value": [
"17428"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-00098"
]
},
{
"id_domain": "City of Hope Medical Center",
... | https://clinicaltrials.gov/study/NCT03440567 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | This phase I trial studies the side effects and best dose of avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma or mantle cell lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as avelumab, utomilumab, ... | A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma | [
{
"description": "Undergo autologous hematopoietic stem cell transplantation",
"name": "Autologous Hematopoietic Stem Cell Transplantation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"AHSCT",
"Autologous Hematopoietic Cell Transplantation",
"Stem Cell T... | [
{
"design_group_description": "Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, ... | [
"Recurrent Diffuse Large B-Cell Lymphoma",
"Recurrent Mantle Cell Lymphoma",
"Refractory Diffuse Large B-Cell Lymphoma",
"Refractory Mantle Cell Lymphoma",
"Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
],
[
{
"name": "阿维单抗",
"lang": "CN"
},
{
"name": "Avelumab",
"lang": "EN"
},
{
"name": "アベルマ... | null |
NCT02115347 | [
{
"id_field": "org_study_id",
"id_value": [
"8835-014"
]
},
{
"id_domain": "Merck Study number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MK-8835-014"
]
},
{
"id_domain": "Pfizer Study number",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT02115347 | Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) | This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants. In Part 1 of the study, participants with moderate hepatic impairment (Child-Pugh score 7-9) and matched healthy participants will be enrolled; depending... | A Phase 1, Non-randomized, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Hepatic Impairment and the Healthy Subjects With Normal Hepatic Function | [
{
"description": "Tablet",
"name": "Ertugliflozin 15 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants receive a single 15 mg oral dose (tablet) of ertugliflozin",
"design_group_title": "Ertugliflozin 15 mg - Moderate Hepatic Impairment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interve... | [
"Type 2 Diabetes Mellitus",
"Hepatic Impairment"
] | [
"Merck Sharp & Dohme Corp."
] | [
"Pfizer Inc."
] | [
[
{
"name": "艾托格列净",
"lang": "CN"
},
{
"name": "Ertugliflozin pidolate",
"lang": "EN"
}
]
] | null |
NCT04844775 | [
{
"id_field": "org_study_id",
"id_value": [
"EHVA P01/ANRS VRI08"
]
},
{
"id_field": "acronym",
"id_value": [
"EHVA P01"
]
}
] | https://clinicaltrials.gov/study/NCT04844775 | A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults | EHVA P01 is an international, phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults. | EHVA P01/ANRS VRI08: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults | [
{
"description": "1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelo... | [
{
"design_group_description": "0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)<br/>0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (... | [
"Healthy Adults"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Chelsea & Westminster Hospital",
"The Medical Research Council",
"University College London Hospitals NHS Foundation Trust",
"Centre hospitalier universitaire Henri-Mondor",
"EuroVacc Foundation",
"Imperial College London"
] | [
[
{
"name": "DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases)",
"lang": "EN"
}
],
[
{
"name": "Drep-HIV-PT1",
"lang": "EN"
}
],
[
{
"name": "CN54gp140(Imperial College London)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EHVA P01/ANRS VRI08"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EHVA P01"
}
] |
NCT01768338 | [
{
"id_field": "org_study_id",
"id_value": [
"IUCRO-0397"
]
},
{
"id_domain": "Indiana University Institutional Review Board",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"1210009882"
]
}
] | https://clinicaltrials.gov/study/NCT01768338 | Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma | The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma. | A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma | [
{
"description": "Ofatumumab with escalating doses of SB-485232",
"name": "Ofatumumab combined with SB-485232",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.",
"design_group_title": "Ofatumumab combined with SB-485232",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5... | [
"Non-Hodgkin's Lymphoma"
] | [
"Indiana University"
] | [
"Novartis AG"
] | [
[
{
"name": "Iboctadekin",
"lang": "EN"
}
],
[
{
"name": "奥法妥木单抗",
"lang": "CN"
},
{
"name": "Ofatumumab",
"lang": "EN"
},
{
"name": "オファツムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04823897 | [
{
"id_field": "org_study_id",
"id_value": [
"PMH-001"
]
},
{
"id_field": "secondary_id",
"id_value": [
"PMH-001"
]
}
] | https://clinicaltrials.gov/study/NCT04823897 | A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours | CCI-001 is a novel colchicine derivative that is being developed by PharmaMatrix Holdings Ltd. (PharmaMatrix). The drug binds to tubulin, a component of the microtubule polymers which are required for a wide range of cellular processes, perhaps most importantly, cell division and mitosis. CCI-001 has been shown to bind... | A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours | [
{
"description": "Part 1 Dose Escalation: CCI-001 will be given intravenously starting at 1.2mg/m2 in the first cohort. The dose escalation between cohorts will depend on adverse event grading, as judged by NCI-CTCAE. Part 1 is complete when the maximum tolerated dose and the recommended expansion dose are dete... | [
{
"design_group_description": "Part 1 Dose-Escalation: CCI-001 will be given at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, and the recommended dose for dose expan... | [
"Cancer: Recurrent and/or Metastatic Solid Tumours"
] | [
"PharmaMatrix Holdings Ltd"
] | [
"University of Alberta"
] | [
[
{
"name": "CCI-001",
"lang": "EN"
}
]
] | null |
NCT03798314 | [
{
"id_field": "org_study_id",
"id_value": [
"MC178A"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-03661"
]
},
{
"id_domain": "Mayo Clinic in Arizona",
"... | https://clinicaltrials.gov/study/NCT03798314 | Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy... | Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma | [
{
"description": "Given IV",
"name": "Nivolumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"BMS-936558",
"MDX-1106",
"NIVO",
"ONO-4538",
"Opdivo"
],
"type": "Biological"
},
{
"description": "Given PO",
"name": "Pomalidom... | [
{
"design_group_description": "Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (nivolumab and pomalidomide)",
"design_group_type": "Experimental... | [
"Recurrent Nervous System Lymphoma",
"Recurrent Primary Vitreoretinal DLBCL",
"Refractory Nervous System Lymphoma",
"Refractory Primary Vitreoretinal DLBCL"
] | [
"Mayo Clinic"
] | [
"National Cancer Institute"
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "泊马度胺",
"lang": "CN"
},
{
"name": "Pomalidomide",
"lang": "EN"
},
{
... | null |
NCT03469583 | [
{
"id_field": "org_study_id",
"id_value": [
"EYP001-104"
]
}
] | https://clinicaltrials.gov/study/NCT03469583 | Drug Drug Interaction Study for EYP001 With Entecavir | This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of EYP100a combined with ETV in healthy men and women dosed in the morning under fasted conditions. | Study of the Drug Interaction of EYP001a With Entecavir in Healthy Subjects | [
{
"description": "EYP001 self administered capsules, morning, with non carbonated water",
"name": "EYP001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"EYP001a"
],
"type": "Drug"
},
{
"description": "Entecavir self administered tablets, morning, with... | [
{
"design_group_description": "EYP001 capsules by mouth",
"design_group_title": "EYP001 dose1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "EYP001 self administered caps... | [
"Hepatitis B, Chronic"
] | [
"ENYO Pharma SA"
] | [
"CPR Pharma Services Pty Ltd."
] | [
[
{
"name": "恩替卡韦",
"lang": "CN"
},
{
"name": "Entecavir",
"lang": "EN"
},
{
"name": "エンテカビル水和物",
"lang": "JP"
}
],
[
{
"name": "Vonafexor",
"lang": "EN"
}
]
] | null |
NCT05507827 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB-64357"
]
},
{
"id_domain": "Clinical Trials Reporting Program Registration",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2022-07232"
]
}
] | https://clinicaltrials.gov/study/NCT05507827 | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure. | Phase I Trial Evaluating the Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-Cell Acute Lymphoblastic Leukemia (ALL) | [
{
"description": "CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration",
"name": "Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)",
"normalized_type": "3d1aa88261d64c038413723970f... | [
{
"design_group_description": "Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells",
"design_group_title": "Dose escalation",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Lymphoid Leukemia"
] | [
"Stanford University"
] | [
"American Society of Hematology",
"National Marrow Donor Program"
] | [
[
{
"name": "CD19/CD22 CAR T cells (Orca Biosystems)",
"lang": "EN"
}
],
[
{
"name": "Orca-T (Orca Bio)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "45e93eaa25a38d2a0e909e2022522e42",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "679"
}
] |
NCT01590823 | [
{
"id_field": "org_study_id",
"id_value": [
"Dabigatran Hemodialysis 2012"
]
}
] | https://clinicaltrials.gov/study/NCT01590823 | An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients | Patients with end stage renal disease carry a high risk for atrial fibrillation (AF) and require oral anticoagulant therapy for prevention of stroke. Often, the oral anticoagulant, warfarin sodium, is prescribed. Managing dialysis patients on warfarin can be fraught will difficulties given the multitude of drug and foo... | Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients | [
{
"description": "All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.",
"name": "Dabigatran Etexilate 110 mg",
"normalized_type": "3d1a... | [
{
"design_group_description": "Single dose of Dabigatran etexilate 110 mg po",
"design_group_title": "Dabigatran etexilate 110 mg",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "All participants will receive a single dosage of dabigatran etexilate 110 m... | [
"Blood Coagulation Disorders"
] | [
"Nova Scotia Health Authority"
] | [
"Capital Health Region",
"University of Montréal",
"Dalhousie University"
] | [
[
{
"name": "甲磺酸达比加群酯",
"lang": "CN"
},
{
"name": "Dabigatran Etexilate Mesylate",
"lang": "EN"
},
{
"name": "ダビガトランエテキシラートメタンスルホン酸塩",
"lang": "JP"
}
]
] | null |
NCT01226849 | [
{
"id_field": "org_study_id",
"id_value": [
"SGH652"
]
},
{
"id_field": "acronym",
"id_value": [
"SGH652"
]
}
] | https://clinicaltrials.gov/study/NCT01226849 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma | Incorporation of rituximab to conventional chemotherapy (R-CHOP) has revolutionalized the frontline treatment of diffuse large B-cell lymphoma (DLBCL), one of the commonest subtype of lymphoma. Although the majority of patients are cured, there still remains a substantial number patients (20-30%) who will relapse despi... | An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma | [
{
"description": "Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended",
"name": "bortezomib, rituximab, ifosphamide, etoposide, carboplatin",
"normalized_type... | [
{
"design_group_description": "bortezomib, rituximab, ifosphamide, etoposide, carboplatin<br/>Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended",
"design_group_... | [
"Diffuse Large B-Cell Lymphoma"
] | [
"Singapore General Hospital Pte Ltd."
] | [
"Janssen-Cilag Ltd."
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SGH652"
}
] |
NCT06206824 | [
{
"id_field": "org_study_id",
"id_value": [
"OP112522"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2023-507075-22"
]
},
{
"id_field": "acronym",
"id_value": [
"LEUCETTA"
]
}
] | https://clinicaltrials.gov/study/NCT06206824 | Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease | Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS) and Alzheimer's Disease (AD).<br/>For Parts 1, 3, 4, 5 and 6, safety and tolerability of an ... | Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety, Tolerability, PK/PD of SAD, MAD and Food Effect of Leucettinib-21 in Healthy Male Subjects, and Single Dose in Subjects With Down Syndrome or Alzheimer's Disease | [
{
"description": "See arm's description.",
"name": "Leucettinib-21",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "A total of 48 healthy male volunteers will be randomized into six consecutive single ascending dose cohorts of 8 subjects, 6 receiving one dose of Leucettinib-21 and 2 receiving placebo.",
"design_group_title": "Part 1 : Single Ascending Doses in Healthy Volunteers",
"desi... | [
"Healthy Volunteers",
"Down Syndrome",
"Alzheimer's Disease"
] | [
"Perha Pharmaceuticals"
] | [
"European Research Council",
"Fondation Jérôme Lejeune"
] | [
[
{
"name": "Leucettinib-21",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LEUCETTA"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.